Czech Technical-UPenn-NYU Team Wins Grand Challenge in US$5-Million MBZIRC2020 Organized by Khalifa University
26.2.2020 17:14:00 EET | Business Wire | Press release
H.E. Dr. Mugheer Khamis Al Khaili, Member of the Executive Council, and Chairman of Department of Community Development today honored the Grand Challenge team winners Czech Technical University-University of Pennsylvania-NYU and winners of the three Challenge categories at the three-day US$5-million Mohamed Bin Zayed International Robotics Challenge (MBZIRC) 2020 that concluded in Abu Dhabi, organizers Khalifa University of Science and Technology announced today.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200226005539/en/
Czech Technical-UPenn-NYU Team Wins Grand Challenge in US$5-Million MBZIRC2020 organized by Khalifa University (Photo: AETOSWire)
The winning teams in all three categories – Challenge 1, 2, and 3 – also received awards from H.E. Dr. Mugheer Khamis Al Khaili at the ceremony.
His Excellency Hussein Bin Ibrahim Al Hammadi, Steering Committee General Chair, MBZIRC 2020, Dr. Arif Sultan Al Hammadi, Steering Committee General Co-Chair, and His Excellency Dr. Mohammed Al Mualla, Steering Committee Member, were present.
Others who attended the ceremony included UAE government officials, Challenge partners, stakeholders from the academia, research, and industry, as well as all the MBZIRC 2020 team members.
The Czech Technical University-University of Pennsylvania-NYU team won the first position in the Grand Challenge. The University of Bonn team came second, while the combined team of Universidad Politecnica Madrid-Universidad Pablo Olvide Poznan University of Technology- Centre National de la Recherche Scientifique won the third place.
The Beijing Institute of Technology topped Challenge 1 category with the Czech Technical University-University of Pennsylvania-NYU team and the University of Tokyo in the second and third places, respectively, while the Czech Technical University-University of Pennsylvania-NYU team won the Challenge 2 category with Nimbro (University of Bonn) and Technical University of Denmark in the second and third places. Challenge 3 was won by University of Seville-Tecnico Lisboa-CATEC team, while the Technical University of Denmark and the University of New South Wales-Sydney tied for the second place.
The 32 finalists, representing 17 countries, were shortlisted out of 134 teams from across the globe that applied to compete in MBZIRC 2020.
Dr. Arif Sultan Al Hammadi said: “The second edition of MBZIRC has emphatically placed MBZIRC as one of the most prestigious competitions in robotics and artificial intelligence globally, while positioning Khalifa University as the leading higher education institution driving innovation in all areas of science, engineering, and newly-emerging technologies.”
Dr. Al Hammadi added: “Congratulations to all the winners of MBZIRC 2020, especially the Grand Challenge winner and winners of all three Challenge categories. However, all the participating teams deserve credit for their commitment, determination and perseverance during the competition, consistently raising the bar of excellence as displayed by various autonomous drones. Through this Challenge, we have witnessed how technology continues to evolve and we firmly believe the advancements demonstrated by these UAVs and UGVs will very soon become part of our everyday lives.”
For more information, please visit: http://www.ku.ac.ae/
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200226005539/en/
Contact information
APCO Worldwide
Abdullah Al Sayed, Account Director, +971504887044
aalsayed@apcoworldwide.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom